Drugs / TAA-CTL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02789228 | Oct 2016 → Apr 2022 overdue | cancer | Children's National Research Institute | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAA-CTL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02789228 ↗ |
| Modality | Cell therapy | “Tumor-associated antigen cytotoxic T cells (TAA-Ts) represent a new, potentially effective and nontoxic therapeutic approach” PMID 31356143 ↗ Jul 2019 |